A randomized phase II trial of mitoxantrone, estramustine and vinorelbine or bcl-2 modulation with 13-cis retinoic acid, interferon and paclitaxel in patients with metastatic castrate-resistant prostate cancer: ECOG 3899

BACKGROUND: To test the hypothesis that modulation of Bcl-2 with 13-cis retinoic acid (CRA)/interferon-alpha2b (IFN) with paclitaxel (TAX), or mitoxantrone, estramustine and vinorelbine (MEV) will have clinical activity in men with metastatic castrate-resistant prostate cancer (CRPC). METHODS: 70 pa...

詳細記述

保存先:
書誌詳細
主要な著者: DiPaola, Robert S, Chen, Yu-Hui, Stein, Mark, Vaughn, David, Patrick-Miller, Linda, Carducci, Michael, Roth, Bruce, White, Eileen, Wilding, George
フォーマット: Artigo
言語:Inglês
出版事項: BioMed Central 2010
主題:
Research
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC2837641/
https://ncbi.nlm.nih.gov/pubmed/20178647
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1479-5876-8-20
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料